365betĚĺÓýÔÚĎßĘŔ˝ç±­

Skip to main content
You have permission to edit this article.
Edit

Sage Therapeutics scraps Alzheimer’s drug development

Trial fails to meet goal of late-stage trial

Sage Therapeutics on Tuesday said it will stop developing its experimental drug, dalzanemdor, for Alzheimer's disease, after it failed to meet the main goal of a late-stage trial, sending its shares down 10% in premarket trading.

The failed drug trial comes months after the company discontinued development of the same drug as a treatment for Parkinson's disease.



Tags



Ă—

Stay Updated in Minutes

Sign up for our flagship newsletter covering all the local news to keep you informed.

Please enter a valid email.
Thank you for subscribing!

I'm not interested

Get up-to-the-minute news sent straight to your device.

Topics

News Alerts

Breaking News

Breaking News (FlagLive!)

Sign Up

Sign up with

Have an account? Log In

You're all set!

Thank you .

Your account has been registered, and you are now logged in.

Check your email for details.

OK

Log In

Admin login Subscribe
Need an account? Sign Up

Reset Password

Submitting this form below will send a message to your email with a link to change your password.

Forgot Password

An email message containing instructions on how to reset your password has been sent to the email address listed on your account.

Email me a log in link

Promotional Offers

No promotional rates found.

Purchase Gift Purchase Access

Secure & Encrypted

Sign in with
Who is this gift for?
Who is this gift from?
Delivery date
What's your billing location?
Subtotal:
Total:
How would you like to pay?

Secure transaction. Secure transaction. Cancel anytime.

You're all set!

Thank you.

Your gift purchase was successful! Your purchase was successful, and you are now logged in.

OK

An error occurred